Acceptance of Artificial Intelligence in Supporting Cancer Patients

Ioannis MANOLITSIS\textsuperscript{a,1}, Lazaros TZELVES\textsuperscript{a}, Georgios FERETZAKIS\textsuperscript{b,c}, Dimitris KALLES\textsuperscript{b}, Vassilios S. VERYKIOS\textsuperscript{b}, Stamatis KATSIMPERIS\textsuperscript{a}, Athanasios ANASTASIOU\textsuperscript{d}, Dimitrios KOUTSOURIS\textsuperscript{d}, Thanos KOSMIDIS\textsuperscript{d}, Charalambos DELIVELIOTIS\textsuperscript{a}, Athanasios PAPATSORIS\textsuperscript{d} and Ioannis VARKARAKIS\textsuperscript{a}

\textsuperscript{a}Second Department of Urology, National and Kapodistrian University of Athens, Sismanogleio General Hospital, Athens, Greece
\textsuperscript{b}School of Science and Technology, Hellenic Open University, Patras, Greece
\textsuperscript{c}Sismanogleio General Hospital, Department of Quality Control, Research and Continuing Education, Marousi, Greece
\textsuperscript{d}National Technical University of Athens (NTUA)
\textsuperscript{e}CareAcross Ltd, London, United Kingdom

Abstract. ASCAPE Project is a study aiming to implement the advances of Artificial Intelligence (AI), to support prostate cancer survivors, regarding quality of life issues. The aim of the study is to determine characteristics of patients who accepted to join ASCAPE project. It results that participants of the study mainly originate from higher-educated societies that are better informed about the potential benefits of AI in medicine. Therefore, efforts should be focused on eliminating patients’ relucancy by better informing them on the potential benefits of AI.

Keywords. Artificial Intelligence, Prostate cancer, Quality of Life

1. Introduction and Background

Recent breakthroughs in Artificial Intelligence (AI) and Big Data analytics provide opportunities to improve many aspects of healthcare. AI is playing a growing role in oncology, including screening and diagnosis [1]. Many cancer patients endure side effects from the disease or its treatment, which can significantly reduce their health-related quality of life (QoL) [2]. Prostate cancer (PCa) is the second most common neoplasm in men, with over 336,000 new diagnoses annually, in Europe [3]. ASCAPE Project is an international study aiming to implement the advances of Artificial Intelligence (AI), in order to support prostate cancer survivors, regarding QoL issues [4]. An AI-based platform was created and trained on large retrospective datasets, regarding QoL issues of prostate cancer patients. The aim of this platform is to provide clinicians with accurate predictions about the emergence of QoL issues in cancer survivors, and suggest appropriate interventions, based on prospective patient data, obtained from

\begin{footnotesize}
\textsuperscript{1}Corresponding Author: Ioannis MANOLITSIS, MD, PhD(c), Second Department of Urology, National and Kapodistrian University of Athens, Sismanogleio General Hospital, Athens, Greece; E-mail: giannismanolit@gmail.com.
\end{footnotesize}
medical records, questionnaires, and wearables. This approach was thoroughly
communicated and explained to all eligible patients, by providing them with a written
consent form. However, a significant number of cancer patients in our Department,
refused to take part in this project. The aim of the current study is to determine
characteristics of cancer survivors who accepted to join the ASCAPE project.

2. Methods and Materials

All PCa patients undergoing radical prostatectomy, regardless of participating in the
ASCAPE project or not, were asked to answer questions regarding their baseline
demographic characteristics, and regarding their perception on the use of internet,
smartphone applications and AI in general.

Test for normal distribution was performed using Shapiro-Wilk statistical test. In case of
continuous data where normal distribution was followed, paired T-test was used for
comparison, while in case of non-normally distributed data, a non-parametric test was
used. More specifically, when two groups were compared, Wilcoxon rank-sum test was
used, while in case of more than 2 groups, Kruskal-Wallis test was utilized. To compare
binary/categorical variables, chi-square test was used, with Yate’s continuity correction
applied as appropriate. Statistical significance was set at p=0.05. All statistical analyses
were performed using R (R statistical software, Vienna, Austria) [5].

3. Results and Discussion

The mean age of participants in the study was 65 years of age (± 4.9), while for non-
participants was 71 years (± 6.5). Reasons for refusal were phone compatibility issues in
62% of cases, and personal reasons in the rest 38%. The analysis revealed that education
level was a significant factor affecting participation, since 70% of non-participants had
completed secondary level of education, as opposed to 75% of participants who reported
acquiring a university degree (p-value<0.001). The place of residence was also a
significant factor, with 81% of participants and 44% of non-participants, living in a
Metropolis (p-value 0.004) (Figure 1). In addition, 53% of non-participants were not
aware of AI as an entity and consequently, its uses in medicine, compared to 17% of
participants in the project (Figure 2). An additional interesting result from the analysis
was, that 75% of participants reported use of a smartwatch in their daily life routine, in
contrast to 88% of non-participants who did not use a smartwatch (p-value<0.001). It is
common knowledge that AI and its applications has been a source of skepticism and
concern over the years, regarding its capabilities, outcomes and trust of people towards
it [6]. As our study shows, societies that are higher-educated, present more trust and
acceptance towards AI, as people are more familiar with its potential advantages in
medicine, are better informed about technological advancements and as a result, they do
not perceive AI with fear of the unknown. On the contrary, patients that originate from
remote societies, with poorer-education levels, have less interaction with technology,
and that still remains the case for the Greek society in many occasions [7]. As a
consequence, accepting AI is hard to achieve in these patients, even though the potential
benefits by its use, are hard to disregard.
4. Conclusion

The use of AI for assessment and improvement of QoL in cancer patients is promising. There are still social barriers against its widespread implementation, focusing mainly on poor-educated and remote societies easier. Therefore, efforts should focus on eliminating participants’ hesitance and fear, by informing them on the applications and uses of artificial intelligence, and highlighting the potential benefits.

Acknowledgements

This research was supported by the ASCAPE project. The ASCAPE project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 875351.
References


